We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -2.56% | 3.80 | 3.70 | 3.90 | 3.90 | 3.80 | 3.90 | 161,416 | 14:57:33 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 1.03M | -13.91M | -0.0644 | -0.59 | 8.2M |
TIDMPOLX
Polarean Imaging PLC
03 May 2023
Polarean Imaging Plc
("Polarean" or the "Company")
Featured company at 2023 ATS Respiratory Innovation Summit
Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers
Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.
The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.
In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.
Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking. Polarean can be found at booth # 2137.
The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators , all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.
Richard Hullihen, CEO of Polarean, said: " The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."
Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI. A listing of these presentations, their title, author, and session time is available below.
Enquiries:
Hot Features
Premium
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw
(Healthcare
Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0)
7867 984 082
RLF Communications (US media mrash@rlfcommunications.com
enquiries) 336-823-5501
Michelle Rash
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEW(TM) (Xenon Xe(129) hyperpolarized). Xe(129) MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.
About The American Thoracic Society (www.thoracic.org)
The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.
XENOVIEW IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.
Adverse Reactions
Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.
Please see full prescribing information at www.xenoview.net
ATS Abstract Title Presentation Abstract Session and Location
Date Number
=============== =========
129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma May 21, 2023 A 1043 Mini Symposium A17.
09:00 - 11:00
Tell me What You See: New Studies In Lung Imaging
Walter E. Washington Convention Center, Room 204
A-C (Level 2)
=============== ========= ====================================================
Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial May 21, 2023 A 1044 Mini Symposium A17.
Lung Disease
09:00 - 11:00
Tell me What You See: New Studies In Lung Imaging
Walter E. Washington Convention Center, Room 204
A-C (Level 2)
=============== ========= ====================================================
Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients May 21, 2023 823 Poster Discussion Session. A23.
With Idiopathic Pulmonary Fibrosis Associate With Lung Function Poster Viewing
Time LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE
09:00 - 09:45 DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD
Poster
Discussion Walter E. Washington Convention Center, Room 209
Time A-C (Level2)
09:45 - 11:00
=============== ========= ====================================================
Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation May 21, 2023 P508 Thematic Poster Session. A69.
in Thoracic Insufficiency Syndrome Poster Viewing
Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy May 21, 2023 P511 Thematic Poster Session. A69.
Poster Viewing AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Time
11:30 - 13:15 Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129 May 21, 2023 P512 Thematic Poster Session. A69.
Poster Viewing AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Time
11:30 - 13:15 Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic May 21, 2023 P513 Thematic Poster Session. A69.
Insufficiency Syndrome Model Poster Viewing
Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized May 21, 2023 P527 Thematic Poster Session. A69.
129Xe Magnetic Resonance Imaging Poster Viewing AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Time
11:30 - 13:15 Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia May 21, 2023 P528 Thematic Poster Session. A69.
Poster Viewing AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
Time
11:30 - 13:15 Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 May 21, 2023 P529 Thematic Poster Session. A69.
MR Spectroscopy Poster Viewing
Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients May 21, 2023 P538 Thematic Poster Session. A69.
With Asthma Poster Viewing
Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis May 21, 2023 P539 Thematic Poster Session. A69.
Poster Viewing
Time AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING
11:30 - 13:15
Walter E. Washington Convention Center, Area E,
Hall C (Lower Level)
=============== ========= ====================================================
Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric May 22, 2023 206 RAPiD: Rapid Abstract Poster Discussion Session.
COVID-19 Survivors Poster Viewing B27.
Time
09:00 - 09:45 EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND
Poster MONITORING
Discussion
Time Walter E. Washington Convention Center, Room 103
09:45 - 11:00 A-B (Street Level)
=============== ========= ====================================================
Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, May 23, 2023 Poster Discussion Session. C106.
Using UTE and Xe MRI Poster Viewing
Time OUT OF THE 'MUC': UPDATES IN PCD AND CF
14:15 - 15:00
Poster Marriott Marquis Washington, Marquis Ballroom,
Discussion Salons 3-4 (Level M2)
Time
15:00 - 16:15
=============== ========= ====================================================
129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation May 24, 2023 602 Poster Discussion Session. D109.
Poster
Viewing Time THE LONG AND THE SHORT OF LONG COVID
12:00 - 12:45
Poster Walter E. Washington Convention Center, Room 201
Discussion (Level 2)
Time
12:45 - 14:00
=============== ========= ====================================================
Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months May 24, 2023 610 Poster Discussion Session. D109.
Poster Viewing
Time THE LONG AND THE SHORT OF LONG COVID
12:00 - 12:45
Poster Walter E. Washington Convention Center, Room 201
Discussion (Level 2)
Time
12:45 - 14:00
=============== ========= ====================================================
Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy May 23, 2023 611 Poster Discussion Session. D109.
CT Poster Viewing
Time THE LONG AND THE SHORT OF LONG COVID
12:00 - 12:45
Poster Walter E. Washington Convention Center, Room 201
Discussion (Level 2)
Time
12:45 - 14:00
=============== ========= ====================================================
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAAJMATMTTMBFJ
(END) Dow Jones Newswires
May 03, 2023 12:00 ET (16:00 GMT)
1 Year Polarean Imaging Chart |
1 Month Polarean Imaging Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
